

Platelet-rich Plasma Therapy for Chronic Cutaneous Wounds Stratified by Etiology: A Systematic Review of Randomized Clinical Trials

Verónica Salgado-Pacheco^{1,2,3}

Montserrat Serra-Mas^{1,4,*}

Marta Otero-Viñas^{1,2,*}

¹ Tissue Repair and Regeneration Laboratory (TR2Lab), Institut de Recerca i Innovació en Ciències de la Vida i de la Salut a la Catalunya Central (IrisCC), Ctra. de Roda, 70 08500 Vic, Barcelona, Spain

² Department of Biosciences, Faculty of Science, Technology and Engineering, University of Vic – Central University of Catalonia (UVic-UCC), C. de la Laura, 13, 08500 Vic, Barcelona, Spain

³ Medicine and Biomedical Sciences, Doctoral School, University of Vic - Central University of Catalonia (UVic-UCC), C. Dr. Junyent, 1 08500 Vic, Vic, Spain

⁴ Department of Experimental and Methodological Sciences. Faculty of Health Sciences and Welfare, University of Vic - Central University of Catalonia (UVic-UCC), C. Sagrada Família, 7, 08500 Vic, Spain.

*** Corresponding authors:**

Marta Otero-Viñas

Email: marta.oter@uvic.cat

Montserrat Serra-Mas

Email: montserrat.serra@uvic.cat




Fig. S1 Search strategy

Table S1. Excluded studies

Study	Exclusion criteria
Amato et al., 2019	Etiology not described
Anitua et al., 2008	Sample size < 20 patients, dropout rate >15%
Bogdan et al., 2014	Not in English
Cervelli et al. 2011	Study design (not RCT), post-traumatic wounds, not autologous PRP
Driver et al., 2006	Dropout rate >15%
Escamilla et al., 2016	Study design*
Ficarelli et al., 2008	Study design (not RCT)
Ganio et al., 1993	Study design (not RCT)
Gude et al., 2019	Non-standard procedure for PRP
Habeeb et al., 2020	Not autologous PRP, traumatic post-surgery wounds
Holloway et al., 1993	Not autologous PRP (single apheresis from donors)
Kastelan et al., 1998	Study design (not RCT), not autologous PRP
Khorvash et al., 2017	Not in English
Knighton et al., 1990	Not autologous PRP
Liu et al., 2016	Not in English

Mohammad et al., 2017	Not in English
Obolenskiy et al., 2014	Etiology not described (mixed wounds)
Rainys et al., 2019	Etiology not described
Samuel et al., 2016	Not autologous PRP
Santoro et al., 2018	Not an article (oral presentation in a meeting)
Singh et al., 2014	Study design (not RCT)
Sriram et al., 2014	Not an article (abstract)
Sylvaine et al., 2020	Not an article (abstract)
Tsachiridi et al., 2019	Dropout rate >15%
Tsai et al., 2019	Etiology not described (comparing diabetic and non-diabetic patients)
Weed et al., 2004	Etiology not described

* The study analyzes ulcers instead of patients.

RCT, Randomized-controlled trial.

PRP, Platelet-rich plasma.

Table S2. PRP application protocol

Study	Etiology	Application mode	Application interval
Ahmed et al., 2017	Diabetic	Platelet gel	Twice weekly
Elsaid et al., 2019	Diabetic	PRP gel	Twice weekly
Gupta et al., 2021	Diabetic	PRP injection	Weekly
He et al., 2020	Diabetic	Topical administration	Once, repeated after 2 weeks if necessary
Kakagia et al., 2007	Diabetic		ND
Karimi et al., 2016	Diabetic	PRP dressing	Only once at the beginning
Li et al., 2015	Diabetic	Topical APG application	Once, repeated after 2 weeks if necessary
Malekpour et al., 2021	Diabetic	PRP gel	Twice weekly
Saad Setta et al., 2011	Diabetic	PRP application	Twice weekly

Elbarbary et al., 2020	Venous	PRP in dressing or injection in edges	Every two weeks
Elgarhy et al., 2020	Venous	ND	Weekly
Helmy et al., 2021	Venous	Intradermal or subdermal injection of PRP	Weekly
Moneib et al., 2018	Venous	Topical PRP gel	ND
Stacey et al., 2000	Venous	Platelet lysate	Twice weekly
Chandanwale et al., 2020	Arterial	Local infiltration	Repeated every 4 th day
Uçar et al., 2020	Pressure	Topical PRP gel	Every 3 days

PRP, Platelet-rich plasma.

ND, Not described.

Table S3. Diabetic ulcers data

Study	Etiology	Arteries affected	Glycemic control	DM duration	Osteomyelitis
Ahmed et al., 2017	Diabetic	Included	Yes	ND	Excluded
Elsaid et al., 2019	Diabetic	Excluded	Yes	Not controlled	Excluded
Gupta et al., 2021	Diabetic	ND	ND	Yes	Excluded
He et al., 2020	Diabetic	Included	Yes	Yes	ND
Kakagia et al., 2007	Diabetic	Excluded	Yes	ND	Excluded
Karimi et al., 2016	Diabetic	Excluded	Yes	Yes	Excluded
Li et al., 2015	Diabetic	Included	Yes	Yes	ND
Malekpour et al., 2021	Diabetic	Excluded	Yes	ND	Excluded
Saad Setta et al., 2011	Diabetic	ND	ND	ND	ND

DM, Diabetes Mellitus.

ND, Not described.

Table S4. Initial wound area

Study	Etiology	Initial wound area	
		Control group	PRP group
Ahmed et al., 2017	Diabetic	(2.2 ± 1.2) x (2.6 ± 0.4) cm	(2.6 ± 0.7) x (2.4 ± 1.1) cm
Elsaid et al., 2019	Diabetic	MLD: 4 ± 1.5 cm MHD: 3.79 ± 1.4 cm	MLD: 4.3 ± 2 cm MHD: 4.6 ± 2.7 cm
Gupta et al., 2021	Diabetic	4.96 ± 2.89 cm ²	5.22 ± 3.82 cm ²
He et al., 2020	Diabetic	9.73 ± 9.72 cm ²	8.43 ± 6.93 cm ²
Kakagia et al., 2007	Diabetic	25.8 ± 15.2 cm ²	28.4 ± 13.6 cm ²
Karimi et al., 2016 *	Diabetic	13.22 ± 9.35 mm ²	6.98 ± 9.82 mm ²
Li et al., 2015	Diabetic	2.9 (1.0-10.5) cm ²	4.1 (1.4-11.4) cm ²
Malekpour et al., 2021	Diabetic		ND
Saad Setta et al., 2011	Diabetic	8.50 (4-20) cm ²	10.25 (5-21) cm ²
Elbarbary et al., 2020	Venous	17.8 ± 5.4 cm ²	16.5 ± 8.2 cm ²
Elgarhy et al., 2020	Venous	15.0 ± 8.30 cm ²	33.70 ± 53.32 cm ²
Helmy et al., 2021	Venous	20.4 ± 18 cm ²	16.7 ± 11 cm ²
Moneib et al., 2018	Venous	2.94 ± 1.22 cm ²	7.97 ± 16.88 cm ²
Stacey et al., 2000	Venous	4.79 ± 8.24 cm ²	5.06 ± 8.7 cm ²
Chandanwale et al., 2020 *	Arterial	2262.5 mm ²	2298.8 mm ²
Uçar et al., 2020	Pressure	4.83 ± 1.34 cm ²	4.70 ± 1.78 cm ²

The table includes the original data provided by the studies.

* The data is represented using various units of measurement according to the original data of the articles.

PRP, Platelet-rich plasma.

MLD, Maximum longitudinal diameter.

MHD, Maximum horizontal diameter.

ND, Not described.